Conference Day Two

7:30 Networking Breakfast & Conference Registration Networking Breakfast & Conference Registration

8:15 Chairperson’s Opening Remarks Chairperson’s Opening Remarks

8:30 Opening Keynote Presentation: New Approaches For Biotech Business Models Syed Kazmi, VP Business Development and Strategic Planning, Ligand Pharmaceuticals Inc. Opening Keynote Presentation: New Approaches For Biotech Business Models Syed Kazmi VP Business Development and Strategic Planning, Ligand Pharmaceuticals Inc. Syed Kazmi has served as Vice President, Business Development and Strategic Planning since July 2007. He has been instrumental in Ligand’s licensing deals and M&A activity including multiple product divestitures, acquisitions of three publically traded pharmaceutical companies (Pharmacopeia, Neurogen and Metabasis), set up and management of multiple strategic alliances with large p [read more]

9:00 Panel: Understanding The Unique Dynamics Of Corporate Venture Capital Nicole J. Walker, Director, Venture Investments, Abbott Biotech Ventures Brian Piper, Senior Director, Strategic Investment Group, Shire Pharmaceuticals Eric T. Olson, Senior Associate, Genzyme Ventures Corporate venture groups operated by Big Pharma companies have become an increasingly important source of funds for biotech companies. Understanding how their business models and strategies are different from their parent company and traditional VC is important when pitching potential investors. The panelists will discuss the various strategies of corporate VCs, the strategies biotech entrepreneurs should use to pitch them, and what to expect from a Big Pharma investor Nicole J. Walker Director, Venture Investments, Abbott Biotech Ventures Brian Piper Senior Director, Strategic Investment Group, Shire Pharmaceuticals Brian is Senior Director, Strategic Investment Group (SIG), for Shire Pharmaceuticals, Inc. Brian has over 18 years operating experience in the biopharmaceutical industry, the last 9 years spent with Shire Pharmaceuticals. While with Shire, Brian has held responsibilities in a variety of roles within the organization, the most recent being as an initial member of the SIG, Shire's corporate venture [read more] Eric T. Olson Senior Associate, Genzyme Ventures Eric Olson is a Senior Associate on the Genzyme Ventures team. Prior to joining Genzyme Ventures, Eric was a Business Development Manager in Genzyme’s Corporate Development group, where he evaluated and led numerous business development opportunities spanning several therapeutics areas and stages of development. Prior to joining Genzyme, Eric was an investment banker at Benedetto, Gartland WBR_AMP [read more]

10:00 Refreshment Break & Networking Opportunity Refreshment Break & Networking Opportunity

10:30 Panel: Effectively Navigating Through The Complexities Of Partnering With Big Pharma And Big Biotech Sanjeev Munshi, Ph.D, MBA, Director, Liscensing and External Research, Mid-Atlantic & Southeastern US, Merck & Co. Inc. Christine Grygon, Head BI Partnering, Boehringer Ingelheim John Gustofson, Director, Business Development, AstraZeneca John Sorvillo, Director, Licensing, External R&D, Amgen Top Big Pharma and Biotech organizations are always re-assessing and fine-tuning their approaches to business development with biotechs. For biotech entrepreneurs, it's challenging to navigate through large organizations and business development teams with intentions of pitching a product. In this session, Big Pharma and Big Biotech will provide an update on their current strategies and advise the audience for the best way to approach their groups for partnerships. Following the update, panelists will take questions from the audience on your more specific challenges in approaching partnerships. Sanjeev Munshi, Ph.D, MBA Director, Liscensing and External Research, Mid-Atlantic & Southeastern US, Merck & Co. Inc. Dr. Sanjeev Munshi is a Director in the External Research and Licensing organization of the Merck Research Laboratories. Sanjeev's role is to identify partnering opportunities that fit with Merck's strategic research and development goals across all therapeutic and technology areas. Sanjeev is primarily responsible for scouting in the Southeastern US.  Dr. Munshi graduated from Kashmir University, [read more] Christine Grygon Head BI Partnering, Boehringer Ingelheim Chris Grygon is Head, BI Partnering in the Business Development and Licensing group at Boehringer Ingelheim Pharmaceuticals. In this role, she is liaison to venture capital and investor communities for Boehringer globally. She has previously held the position of Acting Head, Global Licensing-Oncology, where she had oversight for strategy and evaluation around external alliances for Boehringer’s on [read more] John Gustofson Director, Business Development, AstraZeneca John Gustofson is Director of Strategic Partnering and Business Development at AstraZeneca. In his current position, John is responsible for identifying, evaluating and negotiating early preclinical to late stage clinical opportunities with a focus on Oncology. John has 15+ years professional experience with early stage biotechnology and pharmaceutical industries. In addition, John spent approxima [read more] John Sorvillo Director, Licensing, External R&D, Amgen

11:30 Case Study: Trius Therapeutics And Bayer Form Strategic Collaboration To Develop And Commercialize Torezolid Phosphate Ex-US Berthold Hinzen, Head of BD & Licensing, Global Medicine, Bayer Neil Abdollahian, MS, MBA, Vice President of Corporate Development, Trius Therapeutics In this case study presentation, Trius and Bayer will share details of their exclusive agreement to develop and commercialize Trius' lead Phase 3 antibiotic, torezolid phosphate (torezolid), in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East, excluding North and South Korea. Under the collaboration agreement Trius retains full development and commercialization rights outside the licensed territory including the United States, Canada and the European Union Berthold Hinzen Head of BD & Licensing, Global Medicine, Bayer Neil Abdollahian, MS, MBA Vice President of Corporate Development, Trius Therapeutics Mr. Abdollahian has over 13 years of management and research experience in the life sciences industry. His experience in biopharmaceutical management includes more than 30 transactions ranging from early-stage technology collaborations, clinical-stage licensing transactions to acquisition and divestment of marketed therapeutics and companies. Most recently, Mr. Abdollahian was Director of Business [read more]

12:00 Networking Lunch Networking Lunch

1:30 Panel: Partnering A Platform Technology Today When Companies Want A Drug Tomorrow Chuck Wilson, VP Global Head of Strategic Alliances, Novartis Institutes for BioMedical Research Inc. Jeffrey P. Brennan , SVP, Business & Commercial Development & Chief Business Officer, Targacept Kevin T. Skol, Director, Business Development , ISIS Pharmaceuticals In the current economic climate, platform deals have been taking a back seat to drug development. What are the factors a company considers in building a strategy around a technology platform in comparison to creating a product strategy? This session will discuss how to gain interest from partners and structure the deal. Chuck Wilson VP Global Head of Strategic Alliances, Novartis Institutes for BioMedical Research Inc. Chuck Wilson serves as the Global Head of Strategic Alliances, leading a group responsible for research partnering at Novartis. Partnering efforts include academic relationships to understand disease processes, biotech collaborations to access drug discovery technologies, and in-licensing of compounds prior to clinical proof-of-concept. Prior to joining Novartis, Chuck founded and led Archemix, a [read more] Jeffrey P. Brennan SVP, Business & Commercial Development & Chief Business Officer, Targacept Jeffrey P. Brennan joined Targacept in September, 2003, as Vice President of Business and Commercial Development. Mr. Brennan has more than 25 years of pharmaceutical industry experience, and has held Executive Management positions at : Sanofi-Synthelabo, Inc., from 1996-2003, and most recently at Targacept.Throughout his career, Mr. Brennan has demonstrated success in both strategic development a [read more] Kevin T. Skol Director, Business Development , ISIS Pharmaceuticals Kevin Skol leads the business development activities at Isis Pharmaceuticals as the Director of Business Development. Kevin is primarily responsible for implementing Isis’ innovative partnering structures including its Preferred Partner Alliance model and Satellite Company strategy which now includes over a dozen technology and drug development collaborations. Prior to Isis, Kevin was a marketing [read more]

2:30 Panel: Innovative Strategies To Successfully Conduct Due Diligence In M&A’s, Licensing Agreements And Other Transactions Len Smith, Principal Intellectual Property Counsel, Medicis Pharmaceutical Corporation Kerry Flynn, VP Intellectual Propery, Shire Matthew Porzio, Vice President of Product Marketing, Intralinks Without proper IP due diligence, a potentially lucrative deal can vanish. This session will provide tips for effectively managing the due diligence process including defining the company’s business goals before you begin the due diligence review, analyzing the company’s options when discovering negative information in a late stage of the due diligence review, uncovering the vulnerable spots for licensing deals and crafting an effective due diligence checklist Len Smith Principal Intellectual Property Counsel, Medicis Pharmaceutical Corporation Len has primary responsibility for the management of all IP related matters at Medicis. His work includes negotiating and drafting transactions, conducting due diligence investigations, enforcing IP rights, and developing IP-related strategies.Medicis is engaged in the research, development, and marketing of innovative pharmaceutical products and devices in dermatology and aesthetics. Len holds a [read more] Kerry Flynn VP Intellectual Propery, Shire Kerry Flynn is Vice President for Intellectual Property at Shire. She has over 20 years of experience in the Intellectual Property and Licensing field, and has recently earned the newly released designation of Certified Licensing Professional from the Licensing Executives Society. Ms. Flynn was previously Vice President of Business Development and Intellectual Property at Transkaryotic Therapies, [read more] Matthew Porzio Vice President of Product Marketing, Intralinks Matthew Porzio, Vice President of Product Marketing, joined IntraLinks in August of 2003. He is responsible for driving the development and marketing of IntraLinks' Exchanges including virtual dealroom/dataroom solutions for the M&A and restructuring communities.Before joining IntraLinks, he was a senior associate at Metzler, a German advisory firm, where he focused on cross-border [read more]

3:30 Refreshment Break & Networking Opportunity Refreshment Break & Networking Opportunity

4:00 Case Study: Strategic Outsourcing: Holy Grail Or Moving Sands Francois Nader, President and CEO, NPS Pharmaceuticals Inc. Early 2007, NPS Pharmaceuticals embraced a transformational strategy that resulted in fundamental changes to company’s core focus, culture and business model. The execution of this makeover relied on a strategic outsourcing platform that permeated every aspect of the company. This presentation will discuss NPS’ outsourcing When does strategic outsourcing make sense for your company? What are the key ingredients of successful strategic outsourcing? What are the seen and unforeseen challenges of outsourcing consistent with the goal of “flawless” execution of business plans? Why is there a perpetual temptation to drift back to a FIPCO model? Compliance, compliance and more compliance… And finally, what are the lessons and key takeaways from our experience? Francois Nader President and CEO, NPS Pharmaceuticals Inc. Francois Nader has been president and chief executive officer of NPS Pharmaceuticals, Inc. since March 2008. Dr. Nader joined NPS in June 2006 and served as executive vice president and chief operating officer until March 2008. In that capacity, he was responsible for managing the company’s worldwide research and development, commercial operations, manufacturing and regulatory affairs. Before join [read more]

4:30 Panel: Making It Work After The Deal: Practical Tips For Alliance Management Constantine Chinoporos, VP, Corporate Development, Genzyme Ann Kraft, Executive Director of Licensing and Business Development, Purdue Pharma Rick Hoyt, VP Business Development, Covidien Anthony Recupero, Senior Director, Licensing, Aptalis Pharma Matthew J. Meyer, Vice President, Corporate Development and Legal Affairs, XDx, Inc. Strategic alliances are not just a competitive tool for companies, but a tool for survival and it is important to manage these alliances effectively. This session will cover the key steps and critical factors for successful alliance management. Panelists will give practical tips on what works, what doesn’t work and how to make it work after the ink dries. Constantine Chinoporos VP, Corporate Development, Genzyme Ann Kraft Executive Director of Licensing and Business Development, Purdue Pharma Rick Hoyt VP Business Development, Covidien Anthony Recupero Senior Director, Licensing, Aptalis Pharma Anthony Recupero, Ph.D., serves as Senior Director, Licensing for Pharmaceutical Technologies at Aptalis Pharma (formerly Eurand) where he is responsible for new business development and licensing for North America. Prior to joining Eurand, Dr. Recupero was VP, Business Development at MaxCyte Inc., a cell therapeutics company, where he led all business development and licensing activities. Dr. Rec [read more] Matthew J. Meyer Vice President, Corporate Development and Legal Affairs, XDx, Inc. Matthew Meyer is the Vice President of Corporate Development and Legal Affairs. Mr. Meyer has over 15 years of business development, marketing and commercial legal experience in the domestic and international life sciences industry. Prior to joining XDx, Mr. Meyer was Vice President, Business Development and General Counsel at Cerimon Pharmaceuticals where he led the in-license and partnering of p [read more]

5:30 Networking Cocktail Reception Networking Cocktail Reception